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Abstract
Background This study evaluated the efficacy and safety of
laparoscopic adjustable gastric banding (LAGB) in a large
cohort of morbidly obese patients followed for up to 5 years.
Methods Morbidly obese patients, ≥16 years of age, who
underwent LAGB surgery at the Surgical Weight Loss
Clinic in Ontario, Canada, between May 2005 and January
2011 were eligible for this retrospective chart review.
Electronic files were searched to identify all patients who
met the inclusion/exclusion criteria. Demographics, weights
at baseline and follow-up visits (up to 60 months following
surgery), and post-operative complications were document-
ed. As follow-up visits occurred at unevenly spaced inter-
vals within and across patients, modeling methods were
used to more accurately assess mean % weight loss (WL)
and % excess weight loss (EWL) over time.
Results This study included 2,815 patients (82 % female,
mean age 43 years, mean baseline BMI 44.6 kg/m2)
followed for a mean of 21.8±15.4 months. Complications
developed in 238 patients (8.5 %), the most frequent being
prolapse/slippage (4.2 %), tubing/access port problems
(1.2 %), and explantation (1.2 %). Mean %WL and
%EWL progressed continuously over the first 2.5 years
post-LAGB, plateauing at 20 and 49 %, respectively, for
up to 5 years of follow up. Factors associated with increased
weight loss were time since surgery, greater baseline weight
(excess weight), older age at time of surgery, and male
gender.
Conclusions Weight loss was maintained for up to 5 years
in our population of patients who underwent LAGB for the
treatment of morbid obesity.
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Introduction
Morbid obesity exacts an immense toll on personal
health, increasing the risk of type 2 diabetes, ischemic
heart disease, stroke, hypertension, obstructive sleep ap-
nea, degenerative joint conditions, and multiple cancers.
[1, 2] Conservative weight management techniques, in-
cluding medications, often fail to achieve substantial and
prolonged weight loss in these individuals, hence the
increasing popularity of bariatric surgery.
Laparoscopic adjustable gastric band (LAGB) surgery is
a well-established bariatric procedure that results in substan-
tial and durable weight loss as well as a significant decrease
in obesity-related comorbidities. [3, 4] Compared with other
bariatric procedures, LAGB is associated with lower rates of
complications, shorter hospital stays, lower hospital
readmission rates, and lower mortality rates, and is revers-
ible. [2, 5–7] LAGB can be routinely performed in an
outpatient setting due to the predictable and reproducible
nature of the laparoscopic procedure. [8–11]
An important consideration with any obesity treatment is
the durability of the weight loss that is achieved. [12] A
number of recent publications have documented medium- to
long-term maintenance of significant weight loss with
LAGB. [13–19] The present study adds to that literature
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by evaluating the efficacy and safety of LAGB in a
large cohort of morbidly obese patients or obese pa-
tients with at least one comorbidity who underwent
surgery in an outpatient Canadian center and were followed
for up to 5 years.
Materials and Methods
Study Design, Subjects, and Surgeries
This retrospective chart review included patients who
underwent LAGB surgery at the Surgical Weight Loss
Clinic (SWLC) in Mississauga, Ontario, Canada, between
May 2005 and January 2011. To be included in the analy-
sis, subjects must have had a reliable start date for weight,
been 16 years of age or older, and had a body mass index
(BMI) ≥35 kg/m2 or a BMI ≥30 and <35 kg/m2 with at
least one associated comorbidity. Patients who had previ-
ously undergone bariatric surgery, including those who
underwent LAGB previously through a different surgical
center, were excluded.
The standard pre-operative protocol at SWLC included a
very low calorie diet (VLCD) product (Optifast® or equiv-
alent) for at least 2 weeks prior to surgery in order to reduce
fatty infiltration of the liver. [20, 21] The exact duration of
VLCD varied with the patient's weight at the time of the
surgical consultation.
All LAGB surgeries were performed by one of the au-
thors (CC) or one of the other surgeons at SWLC using
LAP-BAND® Adjustable Gastric Band (Allergan, Inc.,
Irvine, CA, USA) using the standardized pars flaccida tech-
nique as described previously. [11] Allergan 10 cm and VG
bands were used prior to the introduction of the AP System®
which was used beginning in November 2006. Hiatal her-
nias and crural defects were repaired whenever a defect in
the crura was identified.
Patients were followed as per the usual procedures at
SWLC, which includes counseling and band adjustments
as needed. There was no rigid schedule, but generally
follow-ups were monthly for the first 3 months, bi-
monthly through the end of the first year, every 6 months
for the secondyear, then annually or more frequently as
needed. Patients were encouraged to follow up whenever
weight loss slowed, satiety was not present with reduced
portions of food, or if there were symptoms that were
unanticipated.
Electronic Database and Outcome Measures
Electronic files are kept for all patients treated at SWLC,
and these files were searched to identify those who met the
inclusion/exclusion criteria. Baseline demographic data
including age and sex (male/female) were collected for these
individuals, as well as weights at baseline and at each visit
for up to 60 months following surgery, as available. Given
the retrospective nature of this study, patients were not
followed up at pre-defined intervals but rather at intervals
based on patient progress as described earlier.
The main outcome measures were percentage weight
loss (WL) and excess weight loss (EWL). Percentage
excess weight loss (%EWL) was calculated as weight loss
divided by excess weight at baseline, with the quotient
multiplied by 100: %EWL=(BMI at baseline−BMI at
follow-up)/(BMI at baseline−ideal BMI) * 100, where
ideal BMI is assumed to be 25 kg/m2. BMI was calculated
as weight in kg/height in m2.
As part of the usual protocol at SWLC, all known com-
plications are recorded in our medical records. There were
no peri-operative deaths in this series. We have previously
published a detailed report of the short-term complications
of LAGB at our center [11].
Statistical Analysis
Follow-up visits occurred at unevenly spaced intervals with-
in and across patients; therefore, it was not appropriate to
calculate simple arithmetic means at specific time points. To
account for this uneven spacing of weight measurements, a
random coefficient modeling method [22] was used to more
accurately evaluate the mean weight loss and excess weight
loss over time. The 2,815 patients were divided into two
data sets of about equal size. A random sample of one half
of the patients, stratified by gender, was selected to generate
a data set that was used to define the model. The remaining
patients were set aside and used to validate the final model.
Data exploration revealed a weight loss pattern that in-
creased in a curvilinear pattern for approximately 2.5 years
following implantation, at which time a plateau was
reached. Therefore, a nonlinear random coefficients model
was fit using the NLMIXED Procedure of SAS/STAT ver-
sion 9.2. [14] Models for weight loss and excess weight loss
were fit separately. Linear and quadratic terms for time
(days after implantation) were included in the model. We
also examined the effects of selected variables on weight
loss: sex, baseline age, baseline BMI, baseline weight, and
baseline excess weight. These variables and their interac-
tions were tested as covariates in the model. Akaike's infor-
mation criterion (AIC) and statistical significance (alpha=
0.05) were used to judge the form of the final models.
Because mixed modeling methods use all available data,
no imputation for “missing” measurements was necessary.
Complications and adverse events were summarized with
frequencies and percentages using the entire cohort of pa-
tients. All calculations and analyses were performed using
SAS/STAT version 9.2.
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Results
A total of 2,815 patients met the inclusion/exclusion criteria
and were included in this study. Subject demographics
are shown in Table 1. Most patients were female (82 %), with
a mean age of 43 years and a mean baseline BMI of
44.6 kg/m2 (range 27.3 to 102.7 kg/m2). All patients consid-
ered for surgery had a BMI ≥35 kg/m2 or a BMI ≥30 and
<35 kg/m2 with at least one associated comorbidity at the time
of consultation, but may have lost weight with the VLCD as
previously described, and thus had BMI <30 at the time of
surgery.
Patients were followed for a mean of 653.5 days
(21.8 months). The numbers of patients for whom weight
loss data were available over time are shown in Table 1. On
average, patients received 6.2 band adjustments in the first
year and 3.4 adjustments in the second year. Overall, 533 of
2,815 (19 %) patients were defined as lost to follow-up
(LFU; i.e., no recorded visit for at least 18 months prior to
the closure date of the study).
Weight Loss
Both WL and EWL progressed continuously over the first
30 months post-surgery and were maintained for 5 years of
follow-up (Figs. 1 and 2). Mean percent WL and percent
EWL plateaued at 20 and 49 %, respectively, post-LAGB.
Time since surgery was the dominant factor determining the
amount of weight loss, with WL and EWL increasing over
time post-surgery until the plateau was reached at 2.5 years
post-LAGB for %WL (95 % CI 2.46–2.51) and 2.5 years
post-LAGB for %EWL (95 % CI 2.43–2.48).
The next most important variables associated with
weight loss were baseline weight (excess weight), age,
and sex (Figs. 3 and 4). Higher weight at baseline, older
age, and male sex were associated with greater %WL.
Older age and male sex were also associated with greater
%EWL, but patients with higher weights at baseline
actually lost a lower % of excess weight than those with
lower baseline weights. Specifically, patients with higher
baseline weights lost 0.04 % more weight per kilogram,
but 0.05 % less excess weight per kilogram, than those
with lower baseline weights. Older patients realized
0.05 % higher WL and 0.1 % higher EWL for each year
of increased age. Comparing males and females of equal
age and baseline weight, females experienced 0.5 %




as 6 months and
1–5 years for ease of
reference
Characteristic N=2,815
Age (years), mean (SD) 43.3 (10.9)








Baseline weights (kg) by age
<35 years (n=627) 129.2 (31.0)
35 to 50 years
(n=1,416)
124.3 (27.1)
>50 years (n=772) 122.2 (25.2)
Follow up visitsa







Fig. 1 Mean percentage weight loss from pre-surgery baseline. Graph
shows the mean ±95 % confidence intervals (shaded) for the overall
study population
Fig. 2 Mean percentage EWL from pre-surgery baseline. Graph shows
the mean ±95 % confidence intervals (shaded) for the overall study
population
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lower WL than males (not statistically significant) and
3.2 % lower EWL (p<0.0001).
The level at which weight loss plateaued for each indi-
vidual patient depended on the patient's age, sex, and base-
line weight (excess weight). Based on these factors, the
predicted weight loss for an individual patient could be
calculated by the following equations:
%WL ¼ 13:5þ 0:05 ageþ 0:04 baseline weight
 0:5 sex
%EWL ¼ 50:2þ 0:10 age 0:05
 baseline excess weight 3:2 sex
where age is expressed in years, weight and excess weight
are in kilograms, and sex is classified as 0 (male) or 1
(female).
For example, based on the weight loss outcomes of our
patient cohort, a 43-year-old male with a baseline weight of
119 kg and a baseline excess weight of 50 kg would be
expected to reach a plateau of 20.5 % weight loss and
51.9 % excess weight loss at 2.5 years post-surgery. A 43-
year-old female with the same baseline weight and excess
weight would reach a plateau of 20.0 % weight loss and
48.7 % excess weight loss (Figs. 3 and 4).
Model Validation
Model assessment showed that the assumption of nor-
mality was satisfied. The %WL and %EWL models fit
the data set extremely well, meeting the criteria for
judging acceptability of the final models. When tested
using the validation data, the models performed well,
with the mean absolute error (MAE) in %WL ranging
from 2.4 to 11.1 % over time. Results for percent EWL
showed similar trends. MAE for %EWL is higher than
for %WL due to the increased possible range of values
(i.e., patients can lose more than 100 % of their excess
weight, but not 100 % of their weight).
Fig. 3 Mean percentage weight loss from pre-surgery baseline show-
ing the effects of age, baseline weight, and sex. Baseline ages of 28, 43,
and 57 years and weights of 95, 120, and 162 kg are the 10, 50, and 90
quintiles, respectively, of the whole study population. Graphs show the
mean % weight loss for females and males in the 50 % age and baseline
weight quintiles (43 years, 120 kg) and the two groups showing the
largest differences in percentage weight loss at all time points
Fig. 4 Mean percentage excess weight loss from pre-surgery baseline
showing the effects of age, baseline weight, and sex. Baseline ages of
28, 43, and 57 years and excess weights of 29, 50, and 89 kg are the 10,
50, and 90 % quintiles, respectively, of the whole study population.
Graphs show the mean % excess weight loss for females and males in
the 50 % age and baseline excess weight quintiles (43 years, +50 kg)
and the two groups showing the largest differences in percentage
weight loss at all time points
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Complications/Adverse Events
A total of 238 (8.5 %) patients experienced 260 adverse
events (Table 2). The most frequent complications, each
of which occurred in fewer than 5 % of patients, were
proximal pouch dilatation (PPD, prolapse/slippage) (n=
118, 4.2 %), tubing/access port problems (n=35, 1.2 %),
explantation (n=35, 1.2 %), and erosion into the gastric
lumen (n=14, 0.5 %). None of these complications was
severe according to the Parikh classification [5] or life-
threatening. All adverse events resolved with repositioning,
replacement, or removal of the band or adjustment port.
Further analysis of these adverse events is the subject of a
separate publication that is currently in preparation. Nine
patients died during the course of follow-up. Three of the
deaths were due to malignancies, three to myocardial infarc-
tion, one to cerebral aneurysm, one apparent suicide, and one
unknown cause.
Discussion
The main finding of this study was that weight loss was
maintained for up to 5 years in our population of
patients who underwent LAGB for the treatment of
morbid obesity. On average, patients achieved nearly
50 % EWL by 2.5 years post-surgery, which remained
steady in our population followed for up to 3 (n=719),
4 (n=304), and 5 years (n=74). The amount of EWL
documented in the present study agrees closely with the
findings from a review of 35 studies of diabetic patients
who underwent LAGB, where weight loss was found to
progress over the first 2 years post-surgery to reach a mean
of 47 % EWL at 2 years. [23]
The maintenance of weight loss with LAGB found in the
present study is also in line with findings from a number of
other publications. In an Austrian study of 276 patients,
mean EWL was maintained at more than 65 % for 10 years
following LAGB surgery. [16] A French study of 140
patients showed an increase in EWL from 1 to 5 years
following LAGB, for a mean of 46 % EWL at the latter
time point. [13] Similar results have been reported by
other groups and in several meta-analyses, as summarized in
Table 3, although positive long-term results are not universal.
[24, 25]
A number of studies have found that initial loss of excess
weight is greater with gastric bypass than LAGB. [3, 12, 14,
26, 27] However, an analysis of pooled data from 18 gastric
bypass and 18 LAGB studies found that the total EWL over
time was not different between the two procedures at the
later follow-up time points (gastric bypass vs. LAGB: 62 vs.
55 % at 3 years, 58 vs. 55 % at 5 years, and 55 vs. 51 % at
7 years).[3] This suggests that weight loss is more gradual
with LAGB than gastric bypass but that it is just as durable
and of similar magnitude (i.e., weight loss efficacy) over the
long term. One study reported EWL at 7 years to be 58.6 %
with gastric bypass and 46.3 % with LAGB in matched
cohorts of >100 patients per group.[25] The 48 % EWL
with LAGB observed in this study is in line with the liter-
ature showing that patients lose a mean of 43 to 64 % of
excess weight over the long term (Table 3). In the
absence of randomization, it is not possible to conclude
that the apparent differences between LAGB and gastric
bypass reported in the matched cohort study [25] are due
to the procedures themselves (i.e., patient selection fac-
tors on which groups were not matched could have
contributed to the differential weight loss).
Many studies have shown that resolution of obesity-
related comorbidities depends on significant and sustained
weight loss and excess weight loss [28–30]. Results of a
controlled study found that, among individuals who have
had diabetes for less than 2 years, the disease remits in most
patients who lose at least 10 % of their body weight follow-
ing LAGB, whereas the disease does not remit in most
patients who lose less than 10 % of their body weight
following conventional therapy [28]. Two recent prospec-
tive studies exploring mechanisms of type 2 diabetes remis-
sion have demonstrated that early improvements of insulin
sensitivity and intracellular glucose disposition were sec-
ondary to caloric restriction shortly after surgery and from
the amount of weight lost over time.[31, 32] This suggests
that the predominant effect of bariatric surgery on type 2
diabetes is due to weight loss, despite changes in gut hor-
mones. Remission of diabetes was more likely to be
Table 2 Adverse events




Any 238 (8.5 %) 260
Prolapse/slippage 118 (4.2 %) 119
Tubing/access port problems 35 (1.2 %) 39
Explantation 35 (1.2 %) 35
Erosion into gastric lumen 14 (0.5 %) 14
Death 9 (0.3 %) 9
Wound/minor port site infection 8 (0.3 %) 8
Access port site infection 4 (0.1 %) 4
Intraabdominal bleeding 2 (0.1 %) 2
Deep venous thrombosis 2 (0.1 %) 2
Hernia port site 1 (0.0 %) 1
Intraoperative needle lost 1 (0.0 %) 1
Respiratory insufficiency 1 (0.0 %) 1
Small bowel obstruction 1 (0.0 %) 1
Other 24 (0.9 %) 24
OBES SURG (2013) 23:903–910 907
observed in patients with a shorter history and better control
of type 2 diabetes prior to bariatric surgery.[31, 33, 34] A
recent longitudinal study found that diabetes duration
<4 years, body mass >35 kg/m2, and fasting C-peptide
>2.9 ng/mL were pre-operative factors predicting remission
of diabetes at 1 year after gastric bypass.[35] Taken together,
these studies suggest that, in order to achieve remission of
disease, surgical intervention should be considered at an
early phase of diabetes in the obese diabetic patient.
Both LAGB and gastric bypass reduce body weight by
approximately 20–40 % and excess body weight by approx-
imately 50–75 % over the long term.[3, 35, 36] Although
weight loss at 1 to 2 years post-operatively is more rapid
following Roux-en-Y gastric bypass (RYGB) or laparoscop-
ic sleeve gastrectomy (LSG), excess weight loss for LAGB
and LSG over time is similar (50–60 %) and somewhat
lower than that reported for RYGB (60–75 %); however,
morbidity at 1 year is lower for LAGB (5 %) compared to
RYGB and sleeve gastrectomy (11–15 %).[37] Given that
gastric bypass, sleeve gastrectomy, and LAGB surgeries
are all associated with clinically meaningful weight loss,
the choice of bariatric surgery should involve careful
consideration of both surgical and patient factors.
Surgical factors include the expertise and experience of
the treatment center, the risk of surgical complications, the
complexity and reversibility of the procedure, and the
availability of aftercare.[37] In addition, the patient's
weight loss goals, pre-existing comorbidities, willingness
to comply with the required dietary and lifestyle changes,
and the patient's preference are also important factors to
consider when making the decision as to the choice of an
optimal surgical procedure for each patient.[37]
In our model, older age, male sex, and higher baseline
weight were positively associated with post-LAGB WL and
EWL over time. Higher baseline excess weight was
negatively associated with EWL after surgery. Given the
known limitations of %EWL as an outcome measure for
weight loss (e.g., the heavier the patient, the smaller the
%EWL) [38], the effect of baseline WL (in the %WL
model) provides a more clinically meaningful estimate.
Older patients lost more weight than younger patients, and
men lost a higher percentage of excess weight than women
(although there was no difference between men and women
in percentage weight loss).
The model used here is a novel approach to providing
a more accurate assessment of post-bariatric surgery
weight loss in the real-world clinical setting where the
compliance of individual patients to recommended
follow-up visits can be highly variable. The traditional
approach to evaluating post-surgical weight loss parame-
ters is based on simple arithmetic means, which frequent-
ly requires interpolation to “best-fit” the actual patient
visits to pre-determined study time points and may omit
patient data points that do not fit within specified “visit
windows”, introducing additional sources of bias into the
calculation of the population means. The advantages of
the model used here are that it incorporates all data
points for each patient, requires no data reduction or
imputation, and uses the weight loss outcomes achieved
by each individual patient to generate a statistically more
accurate estimate for the mean weight loss outcome for
the overall population.
Further studies are needed to determine whether the pre-
operative patient characteristics used in this model can be
used to provide a clinically relevant prediction of the post-
operative weight loss in an individual patient over time.
Until further data are available, these pre-operative factors
may be of use to the clinician for counseling patients on
expected outcomes based on the baseline characteristics of
the individual patient.
Table 3 Summary of % excess
weight loss with LAGB in the
published literature






Spivak [25] 148/127, ≥ 5 years 46 7 years
Alhamdani [40] 575/312, 2 years/66, ≥ 5 years 40 ≥5 years
Lanthaler [16] 276/221 (estimated from 80 % follow up) 64 10 years
Caiazzo [13] 143/140 46 5 years
Himpens [15] 151/82 43 13 years (median)
Ray [17] 442/135, 3 years/31, 5 years 51 3 years
60 5 years
Garb [14] Meta-analysis of 28 studies 43 1 year (15 studies)
50 2 years (12 studies)
55 3 years (9 studies)
O'Brien [3] Meta-analysis of 18 studies; 4,456,
1 year/3,383, 2 years/640, 5 years
42 1 year (11 studies)
53 2 years (11 studies)
55 5 years (5 studies)
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Adverse events were relatively low in the overall patient
population, with 238 of 2,815 patients (8.5 %) experiencing a
total of 260 adverse events during a mean follow-up of
21 months and a follow-up of 5 years in 74 patients. The most
frequent adverse event in our population was PPD (band
slippage or pouch dilatation), which occurred in 118 patients
(4.2 %). The only other adverse events that occurred in more
than 1 % of patients were tubing/access port problems (n=35;
1.2 %) and band explantation (n=35; 1.2 %). The rates of
adverse events observed in this study are on the low end of
those reported in the literature,[15, 18], although others have
also reported similarly low rates [17]. Adverse events may be
influenced by surgical technique (e.g., pars flaccida, which
was used exclusively in the present study, vs. perigastric) [39],
the type of band used, frequency of follow-up (but not neces-
sarily adjustments), and surgeon experience [11]. Nine (0.3%)
patients in this study population died over the 5 years
encompassed by the analysis. In the eight patients for whom
causes of death could be ascertained, none was believed to be
related to LAGB treatment.
An additional consideration influencing the rate of long-
term LAGB complications pertains to the differences in
healthcare systems in various countries. In Canada, there
may be a greater tendency to revise the band or port rather
than explant the device because wait times for revision pro-
cedures such as gastric bypass surgery may be as long as
3 years. In contrast, revision surgery to remove the band and
perform a second procedure may be more readily available
in the USA and Europe. This may lead to higher rates of
explantation or secondary procedures rather than band re-
tention with revision. Other local and regional factors could
influence the frequency of selected long-term complications
and their management.
Additionally, the percentage of patients LFU in this study
was low (19 %) considering its long-term nature. We rec-
ognize that patients who are lost to follow-up may not be
captured in the reporting of adverse events, and it is possible
that some patients who underwent band explantation did not
report this to our clinic. However, the nature of the Canadian
healthcare system and the limited access to revision surgery
would likely encourage patients with adverse events to
follow up with the clinic at which the band was implanted.
LFU patients are not captured in the weight loss data beyond
their last follow-up time point, and therefore we cannot
make any assumptions as to whether weight loss was
maintained, increased, or decreased over time. This limita-
tion is common to all long-term studies of bariatric surger-
ies, many of which do not report the rates of LFU, thereby
affecting the generalizability of the data presented.
Overall, the present study adds to a growing literature
establishing the medium- to long-term stability of weight
loss with LAGB. Notably, the 5-year weight loss experience
in the outpatient setting reported here is consistent with
other long-term studies demonstrating clinically meaningful
and sustained weight loss outcomes with LAGB.[3]
Consequently, the maintenance of weight loss, combined
with the low rates of adverse events and the ability to
routinely perform the procedure in an outpatient setting,
makes LAGB one of several effective surgical options for
obese patients. As all bariatric surgery procedures require
long-term behavioral and lifestyle changes by the patient, it
is important that the clinician consider both the safety and
efficacy of the surgery, along with patient preferences, to
determine the most appropriate plan for the individual
patient.
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